Biovica moves to Nasdaq First North Premier
Uppsala, March 4, 2019. Biotechnology company Biovica announces today that Nasdaq has approved the company’s application to move from Nasdaq First North to be listed on Nasdaq First North Premier. The transition is an important part of the ambition to be listed on the stock exchange’s main list. The trading of Biovica’s share on Nasdaq First North Premier begins on Monday the 4th of March 2019.
Nasdaq First North Premier gives companies the opportunity to prepare for listing on the stock exchange’s main list by imposing higher demands on information disclosure, accounting principles and corporate governance. The requirements for being listed on First North Premier generally correspond to the regulations that apply on Nasdaq's main list, which is a regulated marketplace. Since the financial year 2017/2018, Biovica reports according to the International Financial Reporting Standards IFRS, a requirement for companies listed on First North Premier.
“When we were listed on Nasdaq First North in March 2017, we had an ambitious development plan that we have delivered according to and we are approaching the commercialization of DiviTum®. In the plan, there have also been thoughts of eventually listing the company on the stock exchange’s main list and listing on Nasdaq First North Premier is a first step in that direction. The move to First North Premier is an important quality mark that opens up for more institutional investors to invest in the company”, says Anders Rylander, CEO of Biovica.
Biovica's shareholders do not need to take any action in connection with the listing on First North Premier. The share will be traded under the same short name and ISIN code as before, BIOVIC-B and SE0008613731, respectively.
Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
In the event of contradictions or differences between the Swedish press release and this English translation of the Swedish press release, the Swedish text shall be given priority.
This information is information that Biovica International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person(s) set out above, at 7.56 CET on March 4, 2019.
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB, email@example.com, +46 8 528 00 399.
Read more: www.biovica.com